Selatogrel Market Size, Forecast, and Emerging Insight - 2032

Selatogrel Market Size, Forecast, and Emerging Insight − 2032

“Selatogrel Market Size, Forecast, and Emerging Insight − 2032” report provides comprehensive insights about selatogrel for myocardial infarction in the seven major markets. A detailed picture of the selatogrel for myocardial infarction in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the selatogrel for myocardial infarction. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the selatogrel market forecast analysis for myocardial infarction in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.

Drug Summary

Selatogrel is a potent, highly selective, fast-acting, and reversible P2Y12 receptor antagonist, being developed for treating AMI in patients at high risk of recurrent AMI. It is self-administered subcutaneously via a drug delivery device (autoinjector) upon the occurrence of symptoms suggestive of an AMI.

Two published Phase II studies, one in patients with chronic coronary syndromes and one in patients with AMI, showed fast and reversible inhibition of platelet aggregation. SC administration of selatogrel 16 mg has demonstrated a rapid onset of action, within 15 min, with the magnitude of the effect extending over approximately 8h. Selatogrel was safe and well-tolerated in both studies.

In June 2021, Idorsia announced the initiation of the Phase III registration study “SOS-AMI” to evaluate the efficacy and safety of self-administered SC selatogrel in suspected AMI.

A special protocol assessment has been agreed upon with the FDA. This indicates the FDA agrees with the adequacy and acceptability of specific critical elements of overall protocol design (e.g., entry criteria, dose selection, endpoints, and planned analyses) for a study intended to support a future marketing application.

The Phase III study with selatogrel is recruiting patients, with a target enrollment of approximately 14,000 patients at high risk of recurrent AMI. Patient recruitment is ramping up as more sites become involved, with a target of more than 500 sites in about 45 countries.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the selatogrel description, mechanism of action, dosage and administration, research and development activities in myocardial infarction.
• Elaborated details on selatogrel regulatory milestones and other development activities have been provided in this report.
• The report also highlights the selatogrel research and development activities in myocardial infarction across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around selatogrel.
• The report contains forecasted sales of selatogrel for myocardial infarction till 2032.
• Comprehensive coverage of the late-stage emerging therapies for myocardial infarction.
• The report also features the SWOT analysis with analyst views for selatogrel in myocardial infarction.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Selatogrel Analytical Perspective by DelveInsight

• In-depth Selatogrel Market Assessment

This report provides a detailed market assessment of selatogrel for myocardial infarction in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

• Selatogrel Clinical Assessment

The report provides the clinical trials information of selatogrel for myocardial infarction covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for myocardial infarction is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence selatogrel dominance.
• Other emerging products for myocardial infarction are expected to give tough market competition to selatogrel and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of selatogrel in myocardial infarction.
• Our in-depth analysis of the forecasted sales data of selatogrel from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the selatogrel in myocardial infarction.

Key Questions

• What is the product type, route of administration and mechanism of action of selatogrel?
• What is the clinical trial status of the study related to selatogrel in myocardial infarction and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the selatogrel development?
• What are the key designations that have been granted to selatogrel for myocardial infarction?
• What is the forecasted market scenario of selatogrel for myocardial infarction?
• What are the forecasted sales of selatogrel in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to selatogrel for myocardial infarction?
• Which are the late-stage emerging therapies under development for the treatment of myocardial infarction?